HLB Pharmaceutical Co., Ltd. (KOSDAQ: 047920)
27,000
+350 (1.31%)
Sep 11, 2024, 1:56 PM KST
HLB Pharmaceutical Balance Sheet
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2019 | FY 2018 | FY 2017 |
---|---|---|---|---|
Period Ending | Dec '19 Dec 31, 2019 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 |
Cash & Equivalents | 2,744 | 2,744 | 3,030 | 5,350 |
Short-Term Investments | 1,310 | 1,310 | 235 | 525 |
Trading Asset Securities | 11,109 | 11,109 | 5,842 | 5,514 |
Cash & Short-Term Investments | 15,163 | 15,163 | 9,107 | 11,389 |
Cash Growth | 66.50% | 66.50% | -20.04% | - |
Accounts Receivable | 7,910 | 7,910 | 6,044 | 6,382 |
Other Receivables | 156.15 | 156.15 | 163.97 | 128.86 |
Receivables | 8,066 | 8,066 | 6,218 | 6,521 |
Inventory | 5,648 | 5,648 | 5,382 | 4,884 |
Prepaid Expenses | 47.26 | 47.26 | 428.26 | 242.13 |
Other Current Assets | 93.85 | 93.85 | 140.41 | 230.82 |
Total Current Assets | 29,018 | 29,018 | 21,275 | 23,267 |
Property, Plant & Equipment | 15,315 | 15,315 | 13,304 | 13,323 |
Long-Term Investments | 146.5 | 146.5 | 1,265 | 1,789 |
Other Intangible Assets | 446.2 | 446.2 | 282.13 | 188.45 |
Long-Term Deferred Tax Assets | 208.27 | 208.27 | 6.99 | 1,002 |
Long-Term Deferred Charges | 629.76 | 629.76 | 129.67 | - |
Other Long-Term Assets | 82.12 | 82.12 | 160.27 | 277.32 |
Total Assets | 45,846 | 45,846 | 36,423 | 39,846 |
Accounts Payable | 2,404 | 2,404 | 4,856 | 2,261 |
Accrued Expenses | 4,593 | 4,593 | 2,092 | 2,241 |
Short-Term Debt | 8,458 | 8,458 | 4,854 | 1,725 |
Current Portion of Long-Term Debt | 780 | 780 | 1,580 | 10,388 |
Current Portion of Leases | 426.67 | 426.67 | - | - |
Current Income Taxes Payable | - | - | 105.9 | - |
Other Current Liabilities | 6,429 | 6,429 | 2,736 | 1,126 |
Total Current Liabilities | 23,092 | 23,092 | 16,224 | 17,741 |
Long-Term Debt | 1,580 | 1,580 | 1,260 | 2,840 |
Long-Term Leases | 1,954 | 1,954 | - | - |
Long-Term Deferred Tax Liabilities | - | - | 314.93 | - |
Other Long-Term Liabilities | 151.41 | 151.41 | 105.72 | 88.99 |
Total Liabilities | 27,943 | 27,943 | 19,425 | 23,045 |
Common Stock | 6,924 | 6,924 | 6,924 | 6,247 |
Additional Paid-In Capital | 8,435 | 8,435 | 17,304 | 15,263 |
Retained Earnings | 1,215 | 1,215 | -8,453 | -5,410 |
Treasury Stock | -5.6 | -5.6 | -5.6 | -5.6 |
Comprensive Income & Other | 1,334 | 1,334 | 1,229 | 707.13 |
Shareholders' Equity | 17,903 | 17,903 | 16,998 | 16,802 |
Total Liabilities & Equity | 45,846 | 45,846 | 36,423 | 39,846 |
Total Debt | 13,198 | 13,198 | 7,694 | 14,953 |
Net Cash (Debt) | 1,965 | 1,965 | 1,413 | -3,564 |
Net Cash Growth | 39.05% | 39.05% | - | - |
Net Cash Per Share | 141.88 | 141.88 | 104.39 | -297.72 |
Filing Date Shares Outstanding | 13.85 | 13.85 | 13.85 | 12.49 |
Total Common Shares Outstanding | 13.85 | 13.85 | 13.85 | 12.49 |
Working Capital | 5,927 | 5,927 | 5,052 | 5,526 |
Book Value Per Share | 1292.83 | 1292.83 | 1227.52 | 1344.92 |
Tangible Book Value | 17,457 | 17,457 | 16,716 | 16,613 |
Tangible Book Value Per Share | 1260.61 | 1260.61 | 1207.15 | 1329.84 |
Land | 1,239 | 1,239 | 1,239 | 1,239 |
Buildings | 8,520 | 8,520 | 8,472 | 8,581 |
Machinery | 9,673 | 9,673 | 8,772 | 9,892 |
Construction In Progress | 382.9 | 382.9 | 183.6 | 136.94 |
Source: S&P Capital IQ. Standard template. Financial Sources.